To evaluate the effects of golimumab therapy on achieving inactive disease or major improvement , as assessed by the Ankylosing Spondylitis Disease Activity Score ( ASDAS ) , and improvements in health-related quality of life ( HRQOL ) and productivity through 2 years in patients with AS .